Viewing data from:

ORPHENGESIC

ANDA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE | A075141 | GALT PHARMACEUTICALS LLC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Orphengesic Forte (2023)

Total Spending

$419K

Total Claims

175

Beneficiaries

Avg Cost/Unit

$30.54

Spending Trend

$57K(2020)→$591K(2021)→$568K(2022)→$419K(2023)

YoY Change:+6.5%

5yr CAGR:+10.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (2)

Sort:

#001 — 385MG;30MG;25MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: May 29, 1998

No patent or exclusivity listings for this strength.

#002 — 770MG;60MG;50MG

0 patents0 exclusivities▾

TABLET;ORAL | Approved: May 29, 1998